- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02241044
Argon Plasma Coagulation for Bleeding Peptic Ulcers
Ivision of Gastroenterology, Department of Internal Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan
Background:
A second endoscopic method added to injection therapy is recommended for high-risk bleeding peptic ulcers. Many endoscopic devices have been proved as useful hemostatic instruments, whereas the hemostatic efficacy of argon plasma coagulation (APC) has not been widely investigated.
Aim:
This study was designed to know whether additional APC treatment could influence the hemostatic efficacy after endoscopic injection therapy in treating high-risk bleeding ulcers.
Methods:
From October 2010 to January 2012, eligible patients who had high-risk bleeding ulcers were admitted to our hospital. They prospectively randomly underwent either APC therapy plus distilled water injection or distilled water injection alone. Pantoprazole infusion was conducted during the fasting period after endoscopy and orally for 8 weeks to encourage ulcer healing. Episodes of rebleeding were retreated with endoscopic combination therapy. Patients who did not benefit from retreatment underwent emergency surgery or transarterial embolization (TAE).
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Patients and methods Study cohort Patients with acute upper gastrointestinal bleeding (AUGIB) who were admitted to Kaohsiung Veterans General Hospital between January 2011 and January 2012 were screened. Inclusion criteria were (i) over 20 years of age and (ii) patients with high-risk peptic ulcer bleeding. Acute hemorrhage from upper gastrointestine was defined as classical presentation with hematemesis, coffee-ground emesis, and/or melena. High-risk bleeding ulcers were defined as participants with stigmata of a bleeding visible vessels (eg, spurting, oozing), a non-bleeding visible vessels (NBVV) or adherent clot.4 A NBVV at endoscopy was defined as a raised red, red-blue or pale hemispheric vessel protruding from the ulcer bed, without active bleeding. An adherent clot was defined as an overlying blood clot that was resistant to vigorous irrigation.
Exclusion criteria were as follows: (i) the presence of another possible bleeding site (eg, gastroesophageal varix, gastric cancer, reflux esophagitis); (ii) coexistence of actively severe ill diseases (eg, septic shock, stroke, myocardial infarction, surgical abdomen); (iii) treatment with an anticoagulant (eg, warfarin); (iv) pregnancy; (v) the presence of operated stomach or; (vi) refusal to participate in the study.
In current study, baseline characteristics of both study groups were collected at the first 24 hours after admission. Some definitions of events were expressed herein: smoking was defined as inhalation of smoke from burning tobacco daily in recent 3 months; habitual consumption of alcohol was defined as participants imbibing alcohol twice or more per week in recent 3 months; shock was considered systolic blood pressure less than 90 mm Hg or diastolic less than 60 mmHg, and heart rate over 100 beats per minute; comorbid diseases included unresolved malignancy, diabetes mellitus, liver cirrhosis, uremia, congestive heart failure, chronic pulmonary obstructive disease and pneumonia; and coagulopathy was defined as prothrombin time > 14 seconds and/or activated partial thromboplastin time > 45 seconds.
Randomization In this prospective, parallel-group, randomized controlled trial, eligible patients were randomized into two groups using opaque-sealed envelopes numbered according to a table of random numbers before the fist therapeutic endoscopy (index endoscopy): the Combined group and the Injection group. Informed consent was obtained from each enrolled participant. Combined group patients received APC therapy following distilled water injection at index endoscopy. Injection group patients underwent distilled water alone at index endoscopy. Thereafter both treatment groups were treated with intravenous pantoprazole (Pantoloc i.v., Nycomed GmbH, Singen, Germany) 40 mg every 12 hours during the first 3 days, followed by oral pantoprazole (Pantoloc, Takeda GmbH, Oranienburg, Germany) 40 mg daily until the end of 56-day study period. Primary end point was rebleeding. Secondary end points included initial hemostasis, the need for surgery, transfusion requirements, the period of hospitalization, severe adverse event (stricture, obstruction or perforation) and death at 30 days postrandomization.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Kaohsiung, Taiwan, 81362
- Division of Gastroenterology, Department of Internal Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- (i) over 20 years of age and (ii) patients with high-risk peptic ulcer bleeding.
Exclusion Criteria:
- (i) the presence of another possible bleeding site (eg, gastroesophageal varix, gastric cancer, reflux esophagitis); (ii) coexistence of actively severe ill diseases (eg, septic shock, stroke, myocardial infarction, surgical abdomen); (iii) treatment with an anticoagulant (eg, warfarin); (iv) pregnancy; (v) the presence of operated stomach or; (vi) refusal to participate in the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: the Combined group
The Combined group patients received Argon plasma coagulation therapy, PSD-60/Endoplasma (Olympus Corporation, Tokyo, Japan), following distilled water injection at index endoscopy.
Then participants were treated with intravenous pantoprazole (Pantoloc i.v., Nycomed GmbH, Singen, Germany) 40 mg every 12 hours during the first 3 days, followed by oral pantoprazole (Pantoloc, Takeda GmbH, Oranienburg, Germany) 40 mg daily until the end of 56-day study period.
|
Argon plasma coagulation therapy was realized by an Olympus electrosurgical unit/APC unit (PSD-60/Endoplasma, Olympus Corporation, Tokyo, Japan), and its catheters were 2.3mm and 3.5 mm equipped with different endoscope channels.7
APC treatment used a coagulation mode at gas flow/power settings of 1.5L/min and 40 watt for duodenal ulcers and 40-60 watt for gastric ulcers.10
Operative distance between the probe and target bleeding ranged from 2 to 8 mm.
Air warranted to be sucked frequently at endoscopy in an attempt at decrease of APC-induced smoke and gastric decompensation, with appropriate treatment of high-risk bleeding ulcers.
Other Names:
Distilled water was then applied in aliquots of 0.5-2.0
mL, at and around the site of target bleeding, up to 25.0 ml if necessary.
Injection amount was determined by endoscopists according to ulcer or vessel size and its location.
|
Placebo Comparator: the Injection group
Injection group patients underwent distilled water alone at index endoscopy.
Then patients were treated with intravenous pantoprazole (Pantoloc i.v., Nycomed GmbH, Singen, Germany) 40 mg every 12 hours during the first 3 days, followed by oral pantoprazole (Pantoloc, Takeda GmbH, Oranienburg, Germany) 40 mg daily until the end of 56-day study period.
|
Distilled water was then applied in aliquots of 0.5-2.0
mL, at and around the site of target bleeding, up to 25.0 ml if necessary.
Injection amount was determined by endoscopists according to ulcer or vessel size and its location.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
rebleeding
Time Frame: up to 30 days
|
Rebleeding was observed for a 30-day study period.
One or more the following criteria were considered as evidence of recurrent bleeding: aspiration of fresh blood from a nasogastric or orogastric tube; pulse rate over 100 beats per minute; a drop in systolic blood pressure exceeding 30 mmHg; or continue coffee ground emesis or melena with a decline in hemoglobin of at least 2g/dL.
|
up to 30 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
mortality
Time Frame: up to 30 days
|
All-cause deaths were recorded.
|
up to 30 days
|
Surgery
Time Frame: up to 30 days
|
the need for surgery wihtin 30 days
|
up to 30 days
|
sever adverse events
Time Frame: up to 30 days
|
Namely, stricture, obstruction and perforation
|
up to 30 days
|
Collaborators and Investigators
Investigators
- Principal Investigator: Huay-Min Wang, MD, Division of Gastroenterology, Department of Internal Medicine, Kaohsiung Veterans General Hospital
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- VGHKS98-CT8-13
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bleeding Ulcers
-
Singapore General HospitalCompletedBleeding Peptic Ulcers DiseaseSingapore
-
National Taiwan University HospitalUnknown
-
Chinese University of Hong KongCompletedGastrointestinal Bleeding | Bleeding Peptic Ulcer | Active BleedingChina
-
Casa Sollievo della Sofferenza IRCCSCompletedUpper Gastrointestinal Bleeding | Peptic UlcersItaly
-
Chinese University of Hong KongTerminated
-
Azienda USL ModenaRecruiting
-
Kaohsiung Veterans General Hospital.Completed
-
AstraZenecaCompleted
-
Chinese University of Hong KongNational Taiwan University Hospital; Okayama University; Tokyo University; Tsuyama... and other collaboratorsCompletedBleeding Peptic UlcerChina
Clinical Trials on Argon plasma coagulation
-
Chinese University of Hong KongShenzhen Hospital of Southern Medical University; The Fifth Affiliated Hospital... and other collaboratorsRecruitingGastric Low Grade Intraepithelial NeoplasiaHong Kong
-
Centre hospitalier de l'Université de Montréal...McGill University Health Centre/Research Institute of the McGill University... and other collaboratorsCompletedHIV Infections | Anus NeoplasmsCanada
-
Federal University of São PauloCompleted
-
Renmin Hospital of Wuhan UniversityNot yet recruitingColorectal Polyp | Post-polypectomy BleedingChina
-
Istituto Clinico HumanitasRecruiting
-
Erbe Elektromedizin GmbHErbe USA IncorporatedRecruitingObesity | AdiposityUnited States
-
Technical University of MunichCompletedDeglutition Disorders | GlobusGermany
-
Centre hospitalier de l'Université de Montréal...University of British Columbia; Unity Health Toronto; Penn State University; University... and other collaboratorsRecruitingColorectal Cancer | Polyp of ColonCanada
-
Assiut UniversityNot yet recruitingGAVE - Gastric Antral Vascular Ectasia
-
Centre of Postgraduate Medical EducationMaria Sklodowska-Curie National Research Institute of OncologyRecruitingBarrett Esophagus | Esophageal Adenocarcinoma | Reflux DiseasePoland